5.02 USD
-0.22 (-4.2%)
We assign a fundamental rating of 2 out of 10 to IMDX. IMDX was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of IMDX have multiple concerns. While showing a medium growth rate, IMDX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year IMDX has reported negative net income.
IMDX had a negative operating cash flow in the past year.
IMDX had negative earnings in each of the past 5 years.
IMDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IMDX has a Return On Assets of -138.33%. This is amonst the worse of the industry: IMDX underperforms 84.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -138.33% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMDX has a better Gross Margin (54.73%) than 76.84% of its industry peers.
IMDX's Gross Margin has declined in the last couple of years.
IMDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMDX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMDX has been increased compared to 5 years ago.
The debt/assets ratio for IMDX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -11.33, we must say that IMDX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.33, IMDX is not doing good in the industry: 75.71% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.33 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
IMDX has a Current Ratio of 2.79. This indicates that IMDX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.79, IMDX is not doing good in the industry: 67.80% of the companies in the same industry are doing better.
IMDX has a Quick Ratio of 2.73. This indicates that IMDX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.73, IMDX is not doing good in the industry: 67.04% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.73 |
3. Growth
3.1 Past
IMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.34%, which is quite impressive.
Looking at the last year, IMDX shows a very strong growth in Revenue. The Revenue has grown by 520.87%.
The Revenue has been decreasing by -5.09% on average over the past years.
EPS 1Y (TTM)38.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.31%
Revenue 1Y (TTM)520.87%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%126.09%
3.2 Future
Based on estimates for the next years, IMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.56% on average per year.
Based on estimates for the next years, IMDX will show a very strong growth in Revenue. The Revenue will grow by 176.33% on average per year.
EPS Next Y73.46%
EPS Next 2Y34.37%
EPS Next 3Y22.56%
EPS Next 5YN/A
Revenue Next Year543.73%
Revenue Next 2Y167.6%
Revenue Next 3Y176.33%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IMDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IMDX's earnings are expected to grow with 22.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.37%
EPS Next 3Y22.56%
5. Dividend
5.1 Amount
No dividends for IMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IMDX (12/8/2025, 1:47:29 PM)
5.02
-0.22 (-4.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners56.62%
Inst Owner ChangeN/A
Ins Owners1.41%
Ins Owner Change43.57%
Market Cap143.87M
Revenue(TTM)4.40M
Net Income(TTM)-60.78M
Analysts78
Price Target7.14 (42.23%)
Short Float %0.44%
Short Ratio1.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.4%
Min EPS beat(2)-58.92%
Max EPS beat(2)-27.88%
EPS beat(4)0
Avg EPS beat(4)-109.34%
Min EPS beat(4)-342.79%
Max EPS beat(4)-7.78%
EPS beat(8)1
Avg EPS beat(8)-83.68%
EPS beat(12)4
Avg EPS beat(12)-68.66%
EPS beat(16)8
Avg EPS beat(16)-45.83%
Revenue beat(2)1
Avg Revenue beat(2)31.84%
Min Revenue beat(2)-10.25%
Max Revenue beat(2)73.92%
Revenue beat(4)3
Avg Revenue beat(4)743.56%
Min Revenue beat(4)-10.25%
Max Revenue beat(4)1553.71%
Revenue beat(8)3
Avg Revenue beat(8)351.14%
Revenue beat(12)5
Avg Revenue beat(12)231%
Revenue beat(16)5
Avg Revenue beat(16)146.85%
PT rev (1m)29.23%
PT rev (3m)29.23%
EPS NQ rev (1m)-16.01%
EPS NQ rev (3m)-16.01%
EPS NY rev (1m)-17.44%
EPS NY rev (3m)-17.64%
Revenue NQ rev (1m)-19.22%
Revenue NQ rev (3m)4.07%
Revenue NY rev (1m)-1.74%
Revenue NY rev (3m)1.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 32.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.83
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0.15
BVpS-0.32
TBVpS-0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -138.33% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% | ||
| FCFM | N/A |
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.39% | ||
| Cap/Sales | 43.62% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.73 | ||
| Altman-Z | -11.33 |
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.31%
EPS Next Y73.46%
EPS Next 2Y34.37%
EPS Next 3Y22.56%
EPS Next 5YN/A
Revenue 1Y (TTM)520.87%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%126.09%
Revenue Next Year543.73%
Revenue Next 2Y167.6%
Revenue Next 3Y176.33%
Revenue Next 5YN/A
EBIT growth 1Y55.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.07%
EBIT Next 3Y9.21%
EBIT Next 5YN/A
FCF growth 1Y18.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.59%
OCF growth 3YN/A
OCF growth 5YN/A
INSIGHT MOLECULAR DIAGNOSTIC / IMDX FAQ
What is the ChartMill fundamental rating of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IMDX.
Can you provide the valuation status for INSIGHT MOLECULAR DIAGNOSTIC?
ChartMill assigns a valuation rating of 1 / 10 to INSIGHT MOLECULAR DIAGNOSTIC (IMDX). This can be considered as Overvalued.
How profitable is INSIGHT MOLECULAR DIAGNOSTIC (IMDX) stock?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) has a profitability rating of 1 / 10.
Can you provide the financial health for IMDX stock?
The financial health rating of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) is 2 / 10.
What is the expected EPS growth for INSIGHT MOLECULAR DIAGNOSTIC (IMDX) stock?
The Earnings per Share (EPS) of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) is expected to grow by 73.46% in the next year.